Haemonetics stock performance snapshot after recent weakness Haemonetics (HAE) has drawn investor attention after a period of share price weakness, with the stock down about 9% over the past month and ...

Haemonetics, which concentrates on hematology products and services, booked revenue of $327 million for the quarter. Although that was 5% down year over year, it handily topped the average analyst ...

Investors in Haemonetics Corporation HAE need to pay close attention to the stock based on moves in the options market lately. That is because the June 18, 2026 $40.00 Call had some of the highest ...

Haemonetics beats Q4 EPS and revenue estimates, shares rise 1.4%, but gross margin falls 120 basis points as the company sets ...

Ratings for Haemonetics (NYSE:HAE) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ...

Haemonetics (HAE) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.24 per share a year ago. These figures ...

Haemonetics Corporation remains a Buy, supported by robust profit margins, strong cash flow, and leading TEG and plasma businesses driving organic growth. HAE reported improved gross and operating ...

The most recent analyst rating on (HAE) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Haemonetics stock, see the HAE Stock Forecast page. According to Spark, ...

It was something of an outlier in booking gains on a bearish day for stocks overall. This was the result of an investor-pleasing quarterly earnings report. Haemonetics, which concentrates on ...